Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models

Biochemical Pharmacology

Volumn 85, Issue 10, 2013, Pages 1424-1432

  Cassinelli, G ^a   Lanzi, C ^a   Tortoreto, M ^a   Cominetti, D ^a   Petrangolini, G ^a   Favini, E ^a   Zaffaroni, N ^a   Pisano, C ^b   Penco, S ^b   Vlodavsky, I ^c   Zunino, F ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Sigma Tau SpA   (Italy)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antiangiogenic agents; Antitumor activity; Heparanase inhibitor; Pediatric sarcomas; SST0001

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANTICOAGULANT AGENT; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 2; GLYCOSIDASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SST 0001; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; EWING SARCOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SARCOMA CELL; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; DRUG SYNERGISM; FEMALE; GLUCURONIDASE; HEPARIN; HUMANS; INDOLES; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OSTEOSARCOMA; PYRROLES; RHABDOMYOSARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876689693     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.02.023     Document Type: Article

References (41)

1. P.A. Thompson, and M. Chintagumpala Targeted therapy in bone and soft tissue sarcoma in children and adolescents Curr Oncol Rep 14 2012 197 205
2. M. Casanova, and A. Ferrari Pharmacotherapy for pediatric soft-tissue sarcomas Expert Opin Pharmacother 12 2011 517 531
3. J. Ritter Bielack SS. Osteosarcoma Ann Oncol 21 2010 vii320 vii325
4. M. Wachtel, and B.W. Schafer Targets for cancer therapy in childhood sarcomas Cancer Treat Rev 36 2010 318 327
5. K.N. Ganjoo New developments in targeted therapy for soft tissue sarcoma Curr Oncol Rep 12 2010 261 265
6. E. Hanna, J. Quick, and S.K. Libutti The tumour microenvironment: a novel target for cancer therapy Oral Dis 15 2009 8 17
7. S-H. Kim, J. Turnbull, and S. Guimond Extracellular matrix and cell signaling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor J Endocrinol 209 2011 139 151
8. L. Fux, N. Ilan, R.D. Sanderson, and I. Vlodavsky Heparanase: busy at the cell surface Cell 34 2009 511 519
9. U. Lindahl, and J.P. Li Interactions between heparan sulfate and proteins-design and functional implications Int Rev Cell Mol Biol 276 2009 105 159
10. I. Vlodavsky, P. Beckhove, I. Lerner, C. Pisano, A. Meirovitz, and N. Ilan Significance of heparanase in cancer and inflammation Cancer Microenviron 5 2011 115 132
11. C.R. Parish, C. Freeman, and M.D. Hulett Heparanase: a key enzyme involved in cell invasion Biochim Biophys Acta 1471 2001 M99 M108
12. V.C. Ramani, Y. Yang, Y. Ren, L. Nan, and R.D. Sanderson Heparanase plays a dual role in driving hepatocyte growth factor (HGF) signaling by enhancing HGF expression and activity J Biol Chem 286 2011 6490 6499
13. V. Vreys, and G. David Mammalian heparanase: what is the message J Cell Mol Med 11 2007 427 452
14. J-P. Li, and I. Vlodavsky Heparin, heparan sulfate and heparanase in inflammatory reactions Thromb Haemost 102 2009 823 828
15. N. Ilan, M. Elkin, and I. Vlodavsky Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis Int J Biochem Cell Biol 38 2006 2018 2039
16. Y. Yang, V. Macleod, H.Q. Miao, A. Theus, F. Zhan, and J.D. Shaughnessy Jr. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis J Biol Chem 282 2007 13326 13333
17. E.A. McKenzie Heparanase: a target for drug discovery in cancer and inflammation Br J Pharmacol 151 2007 1 14
18. I. Vlodavsky, N. Ilan, A. Naggi, and B. Casu Heparanase: structure, biological fnctions and inhibition by heparin-derived mimetics of heparan sulfate Curr Pharm Des 13 2007 2057 2073
19. R.D. Sanderson, and R.V. Iozzo Targeting heparanase for cancer therapy at the tumor-matrix interface Matrix Biol 31 2012 283 284
20. A. Naggi, B. Casu, M. Perez, G. Torri, G. Cassinelli, and S. Penco Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting J Biol Chem 280 2005 12103 12113
21. B. Casu, I. Vlodavsky, and R.D. Sanderson Non-anticoagulant heparins and inhibition of cancer Pathophysol Haemost Thromb 36 2008 195 203
22. K. Dredge, E. Hammond, P. Handley, T.J. Gonda, M.T. Smith, and C. Vincent PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models Br J Cancer 104 2011 635 642
23. H. Zhou, S. Roy, E. Cochran, R. Zouaoui, C.L. Chu, and J. Duffner M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis PLoS ONE 6 2011 e21106
24. J.P. Ritchie, V.C. Ramani, Y. Ren, A. Naggi, G. Torri, and B. Casu SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis Clin Cancer Res 17 2011 1382 1393
25. I. Shafat, M.W. Bern-Arush, J. Issakov, I. Meller, I. Naroditsky, and M. Tortoreto Preclinical and clinical significante of heparanase in Ewing sarcoma J Cell Mol Med 115 2011 1857 1864
26. V. Masola, C. Maran, E. Tassone, A. Zin, A. Rosolen, and M. Onisto Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion BMC Cancer 9 2009 304 313
27. G. Cassinelli, V. Zuco, G. Petrangolini, M. De Cesare, M. Tortoreto, and C. Lanzi The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects Biochem Pharmacol 84 2012 163 171
28. X. Zheng, F. Chu, P.M. Chou, C. Gallati, U. Dier, and B.L. Mirkin Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism Am J Physiol Cell Physiol 296 2009 C65 C74
29. S. Dalal, A.M. Berry, C.J. Cullinane, D.C. Mangham, R. Grimer, and I.J. Lewis Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family Clin Cancer Res 11 2005 2364 2378
30. E. Zcharia, J. Jia, X. Zhang, L. Baraz, U. Lindahl, and T. Peretz Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metallo proteinases PLoS ONE 4 2009 e5181
31. A. Purushothaman, L. Chen, Y. Yang, and R.D. Sanderson Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma J Biol Chem 283 2008 32628 32636
32. R.D. Sanderson, Y. Yang, T. Kelly, V. MacLeod, Y. Dai, and A. Theus Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies J Cell Biochem 96 2005 897 905
33. S. Kamura, Y. Matsumoto, J-I. Fukushi, T. Fujiwara, K. Iida, and Y. Okada Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Racl pathway Br J Cancer 103 2010 370 381
34. K. Ganjoo, and C. Jacobs Antiangiogenesis agents in the treatment of soft tissue sarcomas Cancer 116 2010 1177 1183
35. H.R. Park, K. Min, H.S. Kim, W.W. Jung, and Y.K. Park Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas Pathol Res Pract 204 2008 575 582
36. M.F. Gee, R. Tsuchida, C. Eichler-Jonsson, B. Das, S. Barichel, and D. Malkin Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid Oncogene 24 2005 8025 8037
37. B. Casu, M. Guerrini, S. Guglieri, A. Naggi, M. Perez, and G. Torri Undersulfated and glycol-split heparins endowed with antiangiogenic activity J Med Chem 47 2004 838 848
38. C. Pisano, C. Aulicino, L. Vesci, B. Casu, A. Naggi, and G. Torri Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist Glycobiology 15 2005 1C 6C
39. Y. Bai, J. Li, B. Fang, A. Edwards, G. Zhang, and M. Bui Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors Cancer Res 72 2012 2501 2511
40. E. Charytonowicz, C. Cordon-Cardo, I. Matushansky, and M. Ziman Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell Cancer Lett 279 2009 126 136
41. G.C. Jayson, D.J. Hicklin, and L.M. Ellis Antiangiogenic therapy-evolving view based on clinical trial results Nature Rev 9 2012 297 303